Arcellx, Inc. (NASDAQ: ACLX) related to its sale to Gilead Sciences, Inc. Under the terms of the proposed transaction, Arcellx shareholders are expected to receive $115.00 per share in cash plus one contingent value right of $5.00 per share upon the achievement of certain milestones.